ABEMACICLIB

N/A

Manufactured by Eli Lilly and Company

35,479 FDA adverse event reports analyzed

Last updated: 2026-04-14

About ABEMACICLIB

ABEMACICLIB is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Eli Lilly and Company. The most commonly reported adverse reactions for ABEMACICLIB include DIARRHOEA, FATIGUE, NAUSEA, VOMITING, MALIGNANT NEOPLASM PROGRESSION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ABEMACICLIB.

Top Adverse Reactions

DIARRHOEA5,308 reports
FATIGUE2,109 reports
NAUSEA1,819 reports
VOMITING1,006 reports
MALIGNANT NEOPLASM PROGRESSION979 reports
DECREASED APPETITE820 reports
DEATH737 reports
ASTHENIA734 reports
DRUG INEFFECTIVE697 reports
WHITE BLOOD CELL COUNT DECREASED620 reports
ANAEMIA602 reports
CONSTIPATION581 reports
ABDOMINAL PAIN UPPER565 reports
NEUTROPENIA555 reports
ALOPECIA498 reports
DEHYDRATION498 reports
HEADACHE479 reports
ABDOMINAL PAIN465 reports
MYELOSUPPRESSION457 reports
DYSPNOEA452 reports
WEIGHT DECREASED445 reports
ARTHRALGIA444 reports
PAIN441 reports
OFF LABEL USE412 reports
DIZZINESS398 reports
PRODUCT DOSE OMISSION ISSUE389 reports
BLOOD CREATININE INCREASED385 reports
RASH345 reports
INTERSTITIAL LUNG DISEASE341 reports
MALAISE335 reports
ABDOMINAL DISCOMFORT330 reports
DISEASE PROGRESSION308 reports
PLATELET COUNT DECREASED292 reports
ACUTE KIDNEY INJURY287 reports
PNEUMONIA279 reports
COUGH248 reports
PYREXIA248 reports
HAEMOGLOBIN DECREASED246 reports
THERAPY CESSATION240 reports
DRUG INTOLERANCE239 reports
PNEUMONITIS232 reports
PRURITUS227 reports
THERAPY INTERRUPTED223 reports
NEUTROPHIL COUNT DECREASED219 reports
HOT FLUSH211 reports
PAIN IN EXTREMITY207 reports
COVID 19206 reports
PULMONARY EMBOLISM205 reports
INSOMNIA204 reports
FEELING ABNORMAL203 reports
THROMBOCYTOPENIA197 reports
TASTE DISORDER196 reports
STOMATITIS183 reports
BACK PAIN181 reports
ILLNESS179 reports
URINARY TRACT INFECTION179 reports
RED BLOOD CELL COUNT DECREASED176 reports
THROMBOSIS174 reports
RENAL IMPAIRMENT171 reports
HEPATOTOXICITY168 reports
HEPATIC FUNCTION ABNORMAL164 reports
GASTROINTESTINAL DISORDER163 reports
MUSCLE SPASMS162 reports
ALANINE AMINOTRANSFERASE INCREASED155 reports
NEUROPATHY PERIPHERAL151 reports
ABDOMINAL DISTENSION149 reports
ASPARTATE AMINOTRANSFERASE INCREASED149 reports
DYSPEPSIA148 reports
METASTASES TO BONE148 reports
GAIT DISTURBANCE145 reports
METASTASES TO LIVER137 reports
ANXIETY133 reports
DRUG INDUCED LIVER INJURY133 reports
DRY SKIN133 reports
FALL131 reports
BONE PAIN128 reports
PERIPHERAL SWELLING128 reports
RENAL FAILURE128 reports
HOSPITALISATION124 reports
INFECTION120 reports
MYALGIA120 reports
HEPATIC ENZYME INCREASED115 reports
PLEURAL EFFUSION115 reports
DECREASED IMMUNE RESPONSIVENESS114 reports
LIVER DISORDER109 reports
HYPOAESTHESIA107 reports
DEEP VEIN THROMBOSIS105 reports
DRUG INTERACTION105 reports
HYPOTENSION104 reports
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION104 reports
LEUKOPENIA103 reports
SEPSIS103 reports
DEPRESSION102 reports
DYSPHAGIA101 reports
NASOPHARYNGITIS98 reports
CHILLS96 reports
HYPOKALAEMIA95 reports
LACRIMATION INCREASED95 reports
FLATULENCE93 reports
WEIGHT INCREASED92 reports

Report Outcomes

Out of 17,732 classified reports for ABEMACICLIB:

Serious 52.6%Non-Serious 47.4%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female15,518 (97.4%)
Male402 (2.5%)
Unknown15 (0.1%)

Reports by Age

Age 65374 reports
Age 64363 reports
Age 60360 reports
Age 63357 reports
Age 58332 reports
Age 55312 reports
Age 68309 reports
Age 59308 reports
Age 62304 reports
Age 61293 reports
Age 66293 reports
Age 70287 reports
Age 57279 reports
Age 56260 reports
Age 75258 reports
Age 67257 reports
Age 69254 reports
Age 54252 reports
Age 73252 reports
Age 72247 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with ABEMACICLIB?

This profile reflects 35,479 FDA FAERS reports that mention ABEMACICLIB. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for ABEMACICLIB?

Frequently reported terms in FAERS include DIARRHOEA, FATIGUE, NAUSEA, VOMITING, MALIGNANT NEOPLASM PROGRESSION, DECREASED APPETITE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures ABEMACICLIB?

Labeling and FAERS entries often list Eli Lilly and Company in connection with ABEMACICLIB. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.